I-Mab (IMAB) Stock Price, Quote & News - Stock Analysis (2024)

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers...

11 days ago - PRNewsWire

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlatio...

18 days ago - PRNewsWire

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET Company Participants Sean Fu - Chief Executive Officer (interim) Phillip Dennis - Chief Medical Officer Josep...

4 weeks ago - Seeking Alpha

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bri...

4 weeks ago - PRNewsWire

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md. , Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies...

4 weeks ago - PRNewsWire

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB...

6 weeks ago - PRNewsWire

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md. , Aug. 7, 2024 /PRNewswire/ --I...

7 weeks ago - PRNewsWire

I-Mab Announces Leadership Transitions

ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has app...

2 months ago - PRNewsWire

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...

Other symbols: BMY

4 months ago - PRNewsWire

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

4 months ago - GlobeNewsWire

I-Mab to Participate at the Jefferies Global Healthcare Conference

ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated...

4 months ago - PRNewsWire

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ --I-Mab (the "Company") (NASDAQ: IMAB),a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hi...

5 months ago - PRNewsWire

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat...

6 months ago - PRNewsWire

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB)a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high...

6 months ago - PRNewsWire

I-Mab Reports Full Year 2023 Financial Results and Business Update

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (...

7 months ago - PRNewsWire

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over ...

7 months ago - Seeking Alpha

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarke...

8 months ago - Reuters

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancingI-Mab's potential of differentiated oncolog...

8 months ago - PRNewsWire

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE,Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients a...

11 months ago - PRNewsWire

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercializati...

11 months ago - PRNewsWire

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patie...

11 months ago - PRNewsWire

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients ...

1 year ago - PRNewsWire

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not...

1 year ago - PRNewsWire

AbbVie terminates deal with I-Mab to develop cancer drug

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

Other symbols: ABBV

1 year ago - Reuters

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400...

1 year ago - Seeking Alpha